StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
81
This month
1
This year
7
Publishing Date
2023 - 11 - 02
3
2023 - 10 - 25
2
2023 - 08 - 03
2
2023 - 07 - 19
1
2023 - 07 - 17
1
2023 - 05 - 04
1
2023 - 04 - 20
1
2023 - 02 - 23
2
2023 - 02 - 02
1
2022 - 11 - 03
1
2022 - 10 - 27
1
2022 - 10 - 13
1
2022 - 09 - 08
1
2022 - 08 - 29
1
2022 - 08 - 11
1
2022 - 08 - 09
1
2022 - 08 - 03
1
2022 - 07 - 28
1
2022 - 07 - 18
1
2022 - 06 - 09
1
2022 - 06 - 02
1
2022 - 05 - 24
1
2022 - 05 - 23
1
2022 - 04 - 28
1
2022 - 04 - 14
1
2022 - 02 - 24
1
2022 - 02 - 10
1
2022 - 01 - 24
1
2022 - 01 - 21
2
2022 - 01 - 14
1
2021 - 12 - 14
1
2021 - 12 - 13
1
2021 - 12 - 12
1
2021 - 12 - 09
1
2021 - 11 - 13
1
2021 - 11 - 09
1
2021 - 11 - 05
2
2021 - 10 - 28
1
2021 - 10 - 27
1
2021 - 10 - 19
1
2021 - 10 - 14
1
2021 - 10 - 04
1
2021 - 09 - 10
1
2021 - 09 - 07
1
2021 - 08 - 09
1
2021 - 08 - 05
1
2021 - 08 - 03
1
2021 - 08 - 02
1
2021 - 07 - 21
2
2021 - 05 - 15
1
2021 - 05 - 03
2
2021 - 04 - 29
1
2021 - 04 - 19
2
2021 - 04 - 15
1
2021 - 04 - 11
1
2021 - 04 - 10
1
2021 - 03 - 31
1
2021 - 03 - 23
1
2021 - 01 - 28
1
2021 - 01 - 07
1
Sector
Health technology
81
Tags
Alliances
1
Als
1
Alzheimer’s
2
Biotech
1
Biotech-bay
5
Blood
1
Cardiac
1
Cardiology
1
Cardiovascular
1
Care
1
Clinical-trials-phase-i
1
Clinical-trials-phase-ii
1
Clinical-trials-phase-iii
7
Conference
13
Disease
3
Earnings
21
Events
7
Financial
21
Financial results
13
First
1
Genetic
1
Genetown
12
Givlaari
1
Hypertension
1
Iot
1
Kidney
2
Liver
1
Liver disease
1
N/a
22
Nephropathy
2
Oxlumo
1
Pharmaceutical
1
Pharmaceuticals
5
Phase 1
3
Phase 2
5
Phase 3
19
Positive
15
Positive results
2
Pre-clinical
1
Preclinical
1
Presentation
1
Publication
3
Report
2
Research
3
Results
79
Risk
1
Study
8
System
1
Tcom
1
Technology
2
Therapeutics
1
Topline
7
Treat
1
Treatment
4
Trial
2
Update
6
Year
7
Entities
Abbvie inc.
92
Agnico eagle mines limited
51
Alnylam pharmaceuticals, inc.
81
Amgen inc.
55
Apollo global management, inc
41
Arrival
200
B2gold corp
44
Bank of montreal
41
Barrick gold corporation
50
Beigene, ltd.
52
Biontech se
55
Bnp paribas
82
Bristol-myers squibb company
73
Brookfield asset management inc
54
Coherus biosciences, inc.
48
Cvr partners, lp
52
Cytokinetics, incorporated
44
Eli lilly and company
219
Enbridge inc
42
First bank
95
Fortress biotech, inc.
61
Genmab a/s
48
Gilead sciences, inc.
55
Incyte corporation
77
Ionis pharmaceuticals, inc.
44
Jd.com, inc.
43
Jinkosolar holding company limited
43
Johnson & johnson
248
Kering
89
Lexicon pharmaceuticals, inc.
41
Ligand pharmaceuticals incorporated
47
Lithium corp
61
Marathon petroleum corporation
55
Medies
40
Mediwound ltd.
53
Medtronic plc
45
Morgan stanley
225
Mplx lp
53
Netease, inc.
59
Nextera energy partners, lp
50
Nextera energy, inc.
51
Novartis ag
59
Orange
375
Paid inc
198
Peabody energy corporation
40
Pfizer, inc.
64
Provention bio, inc.
46
Regeneron pharmaceuticals, inc.
89
Sanofi
393
Sempra energy
41
Signature bank
43
T2 biosystems, inc.
44
Takeda pharmaceutical company limited
71
Teekay corporation
49
Teekay tankers ltd.
48
Teva pharmaceutical industries ltd
53
X financial
104
Xencor, inc.
42
Yamana gold inc.
47
Youdao, inc.
46
Symbols
ABBV
1
ALNY
81
BIIB
1
CMPI
1
GILD
1
IONS
2
JNJ
2
LLY
6
MRNA
1
NTLA
2
NVO
6
PFE
1
PLSE
1
REGN
6
RETA
1
SMMT
1
SNY
28
SNYNF
25
TSVT
1
VIR
6
XNCR
4
Exchanges
Nasdaq
81
Nyse
10
Crawled Date
2023 - 11 - 02
2
2023 - 10 - 25
2
2023 - 08 - 03
2
2023 - 07 - 20
1
2023 - 07 - 19
1
2023 - 07 - 17
1
2023 - 05 - 04
1
2023 - 04 - 20
1
2023 - 02 - 23
2
2023 - 02 - 02
1
2022 - 11 - 03
1
2022 - 10 - 27
1
2022 - 10 - 13
1
2022 - 09 - 08
1
2022 - 08 - 29
1
2022 - 08 - 11
1
2022 - 08 - 09
1
2022 - 08 - 03
1
2022 - 07 - 28
1
2022 - 07 - 18
1
2022 - 06 - 09
1
2022 - 06 - 02
1
2022 - 05 - 24
1
2022 - 05 - 23
1
2022 - 04 - 28
1
2022 - 04 - 14
1
2022 - 02 - 25
1
2022 - 02 - 10
1
2022 - 01 - 24
1
2022 - 01 - 21
2
2022 - 01 - 14
1
2021 - 12 - 14
2
2021 - 12 - 12
1
2021 - 12 - 09
1
2021 - 11 - 13
1
2021 - 11 - 09
1
2021 - 11 - 05
2
2021 - 10 - 28
1
2021 - 10 - 27
1
2021 - 10 - 19
1
2021 - 10 - 14
1
2021 - 10 - 04
1
2021 - 09 - 10
1
2021 - 09 - 07
1
2021 - 08 - 09
1
2021 - 08 - 05
1
2021 - 08 - 03
1
2021 - 08 - 02
1
2021 - 07 - 21
2
2021 - 05 - 15
1
2021 - 05 - 03
2
2021 - 04 - 29
1
2021 - 04 - 19
2
2021 - 04 - 15
1
2021 - 04 - 11
1
2021 - 04 - 10
1
2021 - 03 - 31
1
2021 - 03 - 23
1
2021 - 01 - 28
1
2021 - 01 - 07
1
Crawled Time
00:00
3
01:00
1
03:00
1
04:20
1
08:00
1
09:00
1
10:00
1
11:00
1
12:00
8
12:15
2
12:20
2
12:30
1
13:00
16
13:15
2
13:20
3
13:30
1
14:00
5
14:30
3
15:00
4
15:30
1
16:00
2
16:20
2
18:00
2
19:00
4
20:00
1
20:20
2
21:00
2
22:00
6
23:00
2
Source
www.alnylam.com
16
www.biospace.com
59
www.globenewswire.com
6
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
results
entities :
Alnylam pharmaceuticals, inc.
save search
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Published:
2024-04-18
(Crawled : 19:00)
- biospace.com/
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-0.63%
|
O:
-1.17%
H:
1.01%
C:
0.11%
first
conference
financial
results
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Published:
2024-03-20
(Crawled : 13:00)
- biospace.com/
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-1.61%
|
O:
-0.11%
H:
0.43%
C:
-0.01%
cardiology
results
study
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published:
2024-03-05
(Crawled : 16:00)
- biospace.com/
SNY
|
News
|
$47.375
0.48%
300K
|
Health Technology
|
-1.54%
|
O:
1.17%
H:
0.0%
C:
0.0%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-2.83%
|
O:
-0.73%
H:
1.52%
C:
0.5%
positive
blood
care
topline
results
study
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published:
2024-02-22
(Crawled : 00:00)
- biospace.com/
XNCR
|
$18.64
2.36%
76K
|
Health Technology
|
-24.41%
|
O:
-0.87%
H:
2.89%
C:
2.14%
VIR
|
$8.22
1.48%
120K
|
Health Technology
|
-19.88%
|
O:
-0.69%
H:
2.99%
C:
2.59%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-5.78%
|
O:
-0.17%
H:
6.18%
C:
5.4%
year
update
financial
results
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Published:
2024-02-15
(Crawled : 14:30)
- biospace.com/
SNYNF
|
News
|
$92.7
600K
|
Health Technology
|
2.49%
|
O:
1.16%
H:
1.48%
C:
0.89%
SNY
|
News
|
$47.375
0.48%
300K
|
Health Technology
|
1.35%
|
O:
1.86%
H:
0.0%
C:
0.0%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-11.18%
|
O:
-8.62%
H:
2.18%
C:
-1.71%
year
pharmaceuticals
financial
results
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Published:
2024-02-02
(Crawled : 12:00)
- globenewswire.com
TSVT
|
$4.835
3.98%
96K
|
|
-10.4%
|
O:
-1.16%
H:
9.94%
C:
2.34%
SNY
|
News
|
$47.375
0.48%
300K
|
Health Technology
|
-4.51%
|
O:
-0.93%
H:
0.0%
C:
0.0%
REGN
|
News
|
$908.53
0.93%
40K
|
Health Technology
|
-6.02%
|
O:
1.4%
H:
0.28%
C:
-2.68%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-16.65%
|
O:
-1.23%
H:
1.0%
C:
0.17%
year
financial
results
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
Published:
2024-01-29
(Crawled : 14:30)
- biospace.com/
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-18.83%
|
O:
-0.27%
H:
1.32%
C:
1.02%
conference
year
financial
results
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Published:
2023-11-07
(Crawled : 15:00)
- biospace.com/
ABBV
|
News
|
$169.965
1.24%
890K
|
Health Technology
|
18.4%
|
O:
-0.28%
H:
0.0%
C:
0.0%
SMMT
|
$3.8
8.88%
270K
|
Health Technology
|
60.09%
|
O:
-0.46%
H:
6.68%
C:
-11.75%
PLSE
|
$6.97
1.75%
25K
|
Health Technology
|
31.98%
|
O:
0.39%
H:
6.43%
C:
1.92%
BIIB
|
$194.93
0.42%
210K
|
Health Technology
|
-21.93%
|
O:
-0.82%
H:
0.73%
C:
-0.4%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-12.78%
|
O:
1.06%
H:
2.42%
C:
0.76%
therapeutics
financial
results
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Published:
2023-11-02
(Crawled : 00:00)
- biospace.com/
JNJ
|
News
|
$149.575
0.31%
2.5M
|
Health Technology
|
0.1%
|
O:
-0.89%
H:
0.0%
C:
0.0%
XNCR
|
$18.64
2.36%
76K
|
Health Technology
|
4.24%
|
O:
1.32%
H:
0.45%
C:
-1.19%
VIR
|
$8.22
1.48%
120K
|
Health Technology
|
3.98%
|
O:
1.03%
H:
4.07%
C:
4.07%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-7.14%
|
O:
3.4%
H:
0.57%
C:
-0.5%
update
financial
results
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
Published:
2023-11-02
(Crawled : 13:00)
- biospace.com/
SNY
|
News
|
$47.375
0.48%
300K
|
Health Technology
|
1.39%
|
O:
3.0%
H:
0.0%
C:
0.0%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-7.14%
|
O:
3.4%
H:
0.57%
C:
-0.5%
pharmaceuticals
financial
results
Regeneron Reports Third Quarter 2023 Financial and Operating Results
Published:
2023-11-02
(Crawled : 11:00)
- globenewswire.com
SNY
|
News
|
$47.375
0.48%
300K
|
Health Technology
|
1.39%
|
O:
3.0%
H:
0.0%
C:
0.0%
REGN
|
News
|
$908.53
0.93%
40K
|
Health Technology
|
13.76%
|
O:
0.08%
H:
4.96%
C:
3.4%
NTLA
|
$22.63
3.67%
170K
|
Health Technology
|
-14.39%
|
O:
2.35%
H:
1.63%
C:
1.46%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-7.14%
|
O:
3.4%
H:
0.57%
C:
-0.5%
financial
results
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
Published:
2023-10-25
(Crawled : 23:00)
- biospace.com/
SNYNF
|
News
|
$92.7
600K
|
Health Technology
|
-10.43%
|
O:
0.4%
H:
1.29%
C:
1.29%
SNY
|
News
|
$47.375
0.48%
300K
|
Health Technology
|
-11.67%
|
O:
1.43%
H:
0.64%
C:
-0.09%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-11.08%
|
O:
-1.28%
H:
0.58%
C:
-1.46%
publication
results
study
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-10-25
(Crawled : 19:00)
- biospace.com/
SNYNF
|
News
|
$92.7
600K
|
Health Technology
|
-10.43%
|
O:
0.4%
H:
1.29%
C:
1.29%
SNY
|
News
|
$47.375
0.48%
300K
|
Health Technology
|
-11.67%
|
O:
1.43%
H:
0.64%
C:
-0.09%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-11.08%
|
O:
-1.28%
H:
0.58%
C:
-1.46%
disease
alzheimer’s
positive
results
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
Published:
2023-10-19
(Crawled : 13:00)
- biospace.com/
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-11.69%
|
O:
0.13%
H:
0.23%
C:
-2.9%
conference
financial
results
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
Published:
2023-09-07
(Crawled : 14:30)
- biospace.com/
SNY
|
News
|
$47.375
0.48%
300K
|
Health Technology
|
-12.16%
|
O:
1.03%
H:
0.0%
C:
0.0%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-27.63%
|
O:
-0.15%
H:
1.32%
C:
-0.02%
positive
treat
risk
topline
hypertension
cardiovascular
results
study
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Published:
2023-08-03
(Crawled : 20:00)
- globenewswire.com
JNJ
|
News
|
$149.575
0.31%
2.5M
|
Health Technology
|
-12.26%
|
O:
0.19%
H:
0.0%
C:
0.0%
XNCR
|
$18.64
2.36%
76K
|
Health Technology
|
-22.01%
|
O:
7.75%
H:
4.65%
C:
-3.9%
VIR
|
$8.22
1.48%
120K
|
Health Technology
|
-42.02%
|
O:
-0.36%
H:
2.51%
C:
-2.16%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-23.31%
|
O:
-0.42%
H:
0.0%
C:
-1.97%
update
financial
results
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
Published:
2023-08-03
(Crawled : 13:00)
- biospace.com/
SNYNF
|
News
|
$92.7
600K
|
Health Technology
|
-10.05%
|
O:
-1.6%
H:
0.11%
C:
0.11%
SNY
|
News
|
$47.375
0.48%
300K
|
Health Technology
|
-11.26%
|
O:
-3.79%
H:
0.0%
C:
0.0%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-21.03%
|
O:
-1.35%
H:
5.58%
C:
4.38%
pharmaceuticals
financial
results
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
Published:
2023-07-20
(Crawled : 13:00)
- biospace.com/
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-28.99%
|
O:
-0.48%
H:
1.1%
C:
-1.41%
conference
financial
results
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
Published:
2023-07-19
(Crawled : 22:00)
- biospace.com/
SNY
|
News
|
$47.375
0.48%
300K
|
Health Technology
|
-13.43%
|
O:
0.88%
H:
0.0%
C:
0.0%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-30.05%
|
O:
0.74%
H:
0.28%
C:
-2.21%
publication
results
study
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-07-17
(Crawled : 09:00)
- biospace.com/
SNY
|
News
|
$47.375
0.48%
300K
|
Health Technology
|
-12.21%
|
O:
0.02%
H:
0.0%
C:
0.0%
REGN
|
News
|
$908.53
0.93%
40K
|
Health Technology
|
25.28%
|
O:
0.05%
H:
1.33%
C:
0.38%
ALNY
|
$148.99
2.2%
130K
|
Health Technology
|
-26.03%
|
O:
5.53%
H:
5.23%
C:
-2.49%
disease
alzheimer’s
positive
results
← Previous
1
2
3
4
5
Next →
Gainers vs Losers
89%
11%
Top 10 Gainers
MTTR
|
News
M
|
$4.65
167.24%
9.8M
|
AGBA
|
$2.355
88.4%
34M
|
Finance
EDBL
|
News
|
$6.75
79.52%
1.5M
|
CZOO
|
$8.77
75.75%
11M
|
VNRX
|
$0.84
40.0%
2.6M
|
Health Technology
OPRT
|
News
|
$3.01
33.78%
6.8M
|
Finance
MLEC
|
$1.81
29.29%
2M
|
n/a
CMAX
|
$4.12
28.35%
65K
|
Manufacturing
MTC
|
$2.0
28.21%
1.7M
|
Technology Services
PEGY
|
$0.0586
27.95%
130M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.